Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant

BACKGROUND: Resistance to temozolomide (TMZ) greatly limits chemotherapeutic effectiveness in glioblastoma (GBM). Here we analysed the ability of the Inhibitor-of-apoptosis-protein (IAP) antagonist birinapant to enhance treatment responses to TMZ in both commercially available and patient-derived GB...

Descripción completa

Detalles Bibliográficos
Autores principales: Zakaria, Z, Tivnan, A, Flanagan, L, Murray, D W, Salvucci, M, Stringer, B W, Day, B W, Boyd, A W, Kögel, D, Rehm, M, O'Brien, D F, Byrne, A T, Prehn, J H M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815807/
https://www.ncbi.nlm.nih.gov/pubmed/26657652
http://dx.doi.org/10.1038/bjc.2015.420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815807/
https://www.ncbi.nlm.nih.gov/pubmed/26657652
http://dx.doi.org/10.1038/bjc.2015.420

Ejemplares similares